Table 1.

Patients’ characteristics. Numerical variables are presented as median and range, while categorical variables are presented as counts and percentage. CGD: chronic granulomatous disease; CVC: central venous catheter; IDU: intravenous drug users.

Patients (n = 1072)
Age, years	45 [0.2–92]
Gender Male Female	735 (68.6) 337 (31.4)
Aetiological agent Aspergillus Blastomyces Candida Coccidioides Cryptococcus Fusarium Histoplasma Mucormycosis Paracoccidioides Phaeohyphomycosis Scedosporium Other	284 (26.5) 47 (4.4) 222 (20.7) 60 (5.6) 93 (8.7) 21 (1.9) 14 (1.3) 180 (16.8) 31 (2.9) 5 (0.5) 40 (3.7) 36 (3.3)
Site of infection Basicranium Extremities (except foot) Foot Other cranium bones Pelvis and hip Ribs and sternum Shoulder Splanchnocranium Vertebrae	66 (6.2) 290 (27) 48 (4.5) 91 (8.5) 62 (5.8) 118 (11) 35 (3.3) 265 (24.7) 318 (29.7)
Risk factors Bedsores CGD COVID-19 CVC Diabetes mellitus Disseminated fungal infection Fungemia HIV Hospitalised < 6 months IDU Oncohaematological disease Other immunodepression Parental nutrition Prosthesis Transplant Surgery/local lesion	5 (0.5) 15 (1.4) 57 (5.3) 72 (6.7) 261 (24.3) 234 (21.8) 74 (6.9) 23 (2.1) 155 (14.5) 43 (4) 149 (13.9) 198 (18.5) 22 (2) 31 (2.9) 91 (8.5) 288 (26.9)
Diagnosis Empirical Microbiological isolate from bone Histological Other microbiological methods Radiological	23 (2.1) 878 (81.9) 785 (73.2) 125 (11.7) 826 (77)
Time to diagnosis 0–1 month 1–6 months >6 months	279 (26) 381 (35.5) 97 (9)
Outcome Death Recovery Recurrence/chronicity	113 (10.5) 781 (72.8) 118 (11)
Treatment Duration, months Known antifungal ≥ 1 Known antifungal ≥ 2 Empirical Surgery	4 [0–48], 23 * 877 (81.8) 533 (49.7) 35 (3.3) 705 (65.8)

* Patients who required chronic treatment.